Galectin Therapeutics Submits IND Application for Treatment of Fatty Liver Disease
Posted on January 31, 2013 at 09:02 AM EST
Galectin Therapeutics (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on January 30, 2013. The IND application supports a proposed indication of GR-MD-02 for treatment